The Nitrogen Atoms Are In N-c(=n)-n Groups (e.g., Streptomycin, Etc.) Patents (Class 514/37)
-
Patent number: 11723884Abstract: Provided herein are epinephrine spray formulations and methods of administering the same. Also provided herein are methods of treating anaphylaxis by administering epinephrine spray formulations to subjects in need of such treatment. The spray formulations contain epinephrine or a pharmaceutically acceptable salt thereof, one or more of an antioxidant, an antimicrobial preservative, an isotonicity agent, an absorption enhancer, a viscosity modifier, and/or a buffering agent.Type: GrantFiled: July 16, 2020Date of Patent: August 15, 2023Assignee: Bryn Pharma, LLCInventors: Steven Hartman, Michelle Lobel, Matthew P. Robben, Kenneth L. Dretchen, Michael Mesa
-
Patent number: 11369572Abstract: A delivery vehicle, for delivering a pharmaceutically active agent or a marker to a cell, comprising a ligand binding portion specific for a Fas Ligand, and a carrier for the pharmaceutically active agent or marker.Type: GrantFiled: July 21, 2010Date of Patent: June 28, 2022Assignee: Queen Mary & Westfield CollegeInventors: Davidson Day Ateh, Joanne Elizabeth Martin
-
Patent number: 10959429Abstract: An aqueous disinfectant formulation comprising at least one phenolic compound of natural origin; a surfactant sufficient to form a solution or dispersion of the essential oil in an aqueous carrier; a solvent, and sufficient water to make 100 weight percent is described herein.Type: GrantFiled: March 31, 2020Date of Patent: March 30, 2021Assignee: LABORATOIRE M2Inventors: François Daigle, Ann Letellier, Sylvain Quessy
-
Patent number: 9457033Abstract: The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.Type: GrantFiled: February 15, 2012Date of Patent: October 4, 2016Assignee: SOCPRA SCIENCES ET GENIE, S.E.C.Inventors: François Malouin, Gabriel Mitchell, Kamal Bouarab, Eric Marsault, Felix Chagnon, Simon Boulanger, Isabelle Guay
-
Patent number: 9433685Abstract: The invention provides methods of delivering pharmacologic agents linked to an internalization peptide, in which an inflammatory response inducible by the internalization peptide is inhibited by co-administration of an anti-inflammatory or by linking the internalization peptide to biotin or similar molecule. Such methods are premised in part on the results described in the examples whereby administration of a pharmacological agent linked to tat at high dosages is closely followed by an inflammatory response, which includes mast cell degranulation, histamine release and the typical sequelae of histamine release, such as redness, heat, swelling, and hypotension.Type: GrantFiled: December 29, 2014Date of Patent: September 6, 2016Assignee: NONO INC.Inventors: Michael Tymianski, Jonathan David Garman, Hong Cui
-
Publication number: 20150147380Abstract: Unpurified or low pure soy phosphatidylserine is used to make cochleates. The cochleates contain about 40-74% soy phosphatidylserine, a multivalent cation and a biological active. A preferred cochleate contains the antifungal agent amphotericin B.Type: ApplicationFiled: January 29, 2015Publication date: May 28, 2015Inventors: RAPHAEL MANNINO, RUYING LU
-
Publication number: 20150011488Abstract: Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins are applied (A) directly to a genital wart in the form of a cream, ointment, paste or solution, (B) directly to the genital wart wherein such cream, ointment, paste or solution contains as an additional active ingredient a skin permeabilizing agent, (C) following electrosurgical resection or removal of the genital wart in such form of a cream, ointment, paste or solution, (D) following chemical resection or extirpation of the genital wart in such form, (E) following surgical resection or removal of the genital wart in such form, wherein said Epicatechins, Epicatechin Oligomers, or Thiolated Epicatechins both provide antiviral activity against multiple strains of human pappilomavirus (HPV) and promote healing following resection polymers contained in a vehicle. Disclosed are the compositions, therapeutical kits containing such composition, methods of treatment using such composition, and methods of enhancing the stability of such composition.Type: ApplicationFiled: March 10, 2014Publication date: January 8, 2015Applicant: CACAO BIO-TECHNOLOGIES, LLCInventors: Daniel PRESTON, Randall B. MURPHY
-
Publication number: 20140356457Abstract: This invention relates to a method of identifying a modulator of an NADPH oxidase, whereby said modulator is suitable as a lead compound and/or as a medicament for the treatment and/or prevention of hearing loss and/or phantom hearing, the method comprising the steps of (a) contacting a test compound with a protein, wherein said protein (i) comprises or consists of the amino acid sequence of any one of SEQ ID NO: 1, 3 or 5, or (ii) is encoded by a nucleic acid comprising or consisting of the sequence of any one of SEQ ID NO: 2, 4, 6, 23 or 24, or (iii) is a fragment of the protein according to (i) or (ii) and exhibits NADPH oxidase activity, or (iv) has a sequence at least 75% identical with the protein according to (i) or (ii) or with the fragment according to (iii) and exhibits NADPH oxidase activity, and optionally with one or more NADPH oxidase subunits, under conditions allowing binding of said test compound to said protein or, if present, said subunit(s); (b) optionally determining whether said test comType: ApplicationFiled: April 7, 2014Publication date: December 4, 2014Applicant: UNIVERSITY OF GENEVAInventors: Karl-Heinz KRAUSE, Botond BANFI
-
Patent number: 8889733Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: GrantFiled: January 14, 2013Date of Patent: November 18, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul Wahab, Christian D. A. Fozing, Atta-ur Rahman
-
Patent number: 8889153Abstract: A compound comprising combination of an immunomodulator and to at least one anti-pathogenic agent for treating of facultative or strict infections caused by intracellular microorganisms, the components of the combination or association of substances of the invention, the immunomodulator (proteic aggregate of ammonium and magnesium phospholinoleate-palmitoleate anhydride) and at least one substance with antimicrobial properties can be administered either jointly, simultaneously, consecutively or sequentially, in an appropriate form, according to their chemical properties, and in a dose effective against microorganisms in human and animals.Type: GrantFiled: January 27, 2009Date of Patent: November 18, 2014Inventor: Iseu da Silva Nunes
-
Publication number: 20140328896Abstract: Provided are methods and compositions for enhancing the gastrointestinal health of an animal in need thereof by administering a gastrointestinal health maintaining or improving amount of a composition comprising an effective amount of lactic acid. The administered composition may also comprise one or more prebiotic, probiotic, symbiotic, anti bacterial, or anti-diarrhea agents.Type: ApplicationFiled: December 29, 2011Publication date: November 6, 2014Applicant: HILL'S PET NUTRITION, INC.Inventors: Dennis Jewll, Luis J. Montelongo, Sarah Martinez, Lynda Melendez
-
Publication number: 20140323422Abstract: The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates to processes for the preparation of the conjugates. Such conjugates are useful in the prophylaxis and/or treatment of disease conditions and in particular chronic disease conditions such as inflammatory (including allergic) diseases, metastatic cancers and infection by pathogenic agents including bacteria, viruses or parasites.Type: ApplicationFiled: July 10, 2014Publication date: October 30, 2014Inventors: Warren Charles KETT, Yugang CHEN
-
Publication number: 20140256616Abstract: Modified green tea polyphenols and methods of their use are provided. One aspect provides compounds and compositions containing green tea polyphenols with one on more ester-linked fatty acids.Type: ApplicationFiled: May 19, 2014Publication date: September 11, 2014Applicant: Georgia Regents Research Institute, Inc.Inventor: Stephen D. Hsu
-
Publication number: 20140256664Abstract: The present application discloses rapid Mycobacterium tuberculosis drug susceptibility utilizing real-time PCR of mycobacteriophage D29 DNA. One protocol involves culturing Tb isolates for 48 hours with and without drugs at critical concentrations, followed by incubation with 103 pfu/ml of D29 mycobacteriophage for 24 hours and then real-time PCR. Many drugs can be incubated instantly with Tb and phage. The change in phage DNA real-time PCR cycle threshold (Ct) between control Tb and Tb treated with drugs was calculated and correlated with conventional agar proportion drug susceptibility results. Specifically, 9 susceptible clinical isolates, 22 MDR, and 1 XDR Tb strains were used and Ct control?Ct drug cutoffs of between +0.3 and ?6.0 yielded 422/429 (98%) accurate results for the drugs tested. The Ct values correlated with isolate minimal inhibitory concentration (MIC) for most agents. This D29 qPCR assay offers a rapid, accurate, 1-3 day phenotypic drug susceptibility test.Type: ApplicationFiled: May 11, 2012Publication date: September 11, 2014Applicant: University of Virginia Patent FoundationInventors: Eric R. Houpt, Kimberly A. Kelly, Suporn Pholwat
-
Publication number: 20140248288Abstract: The invention relates to biodegradable, metal alloy-containing compositions, methods for their preparation and applications for their use. The compositions include magnesium and other components, such as yttrium, calcium, silver, cerium, and zirconium; or zinc, silver, cerium, and zirconium; or aluminum, zinc, calcium, manganese, silver, yttrium; or strontium, calcium, zinc. The compositions are prepared by vacuum induction/crucible melting together the components and casting the melted mixture in a preheated mild steel/copper mold. In certain embodiments, the compositions of the invention are particularly useful for forming medical devices for implantation into a body of a patient.Type: ApplicationFiled: October 5, 2012Publication date: September 4, 2014Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATIONInventors: Prashant N. Kumta, Da-Tren Chou, Daeho Hong, Partha Saha
-
Patent number: 8802707Abstract: This invention is a method of killing the stealthy intra-cellular bacteria which are key to the pathogenesis Cancers. These very tiny L-form Cell-Wall-Deficient (CWD) antibiotic-resistant bacteria live within the cytoplasm of cells, including the phagocytic cells (e.g. monocytes, macrophages, lymphocytes, neutrophils and polymorphonuclear cells) of the immune system itself. The cellular proliferation in Cancer is catalysed the action of the same tiny L-form bacteria. They cause the cell nucleus to release mRNA signaling the Th1 cytokine cascade without the need for conventional signaling via, for example, CD4+T -Lymphocytes. Some of these Cytokines and Chemokines, including, without limitation, Cellular Adhesion Molecule (CAM), create the environment which allows the cellular proliferation to start, and then allows the cancerous growth to gain a foothold in the body. Killing these stealthy pathogens removes the environment needed to initiate and feed the cellular proliferation commonly called ‘Cancer’.Type: GrantFiled: July 31, 2006Date of Patent: August 12, 2014Inventor: Trevor Gordon Marshall
-
Publication number: 20140200189Abstract: Artonin I is reported to treat multi-drug resistant Staphlococcus infections.Type: ApplicationFiled: January 14, 2013Publication date: July 17, 2014Inventors: Muhammad Iqbal Choudhary, Saba Farooq, Atia-tul-Wahab, Christian D.A. Fozing
-
Publication number: 20140187423Abstract: The present invention relates to substituted 1-{2-[2-halo-4-(4-halogen-phenoxy)-phenyl]-2-alkoxy-hexyl}-1H-[1,2,4]triazole compounds of formula I as defined in the description, and the N-oxides, and salts thereof, processes and intermediates for preparing these compounds and also to compositions comprising at least one such compound. The invention also relates to the use of such compounds and compositions for combating harmful fungi and seed coated with at least one such compound.Type: ApplicationFiled: August 14, 2012Publication date: July 3, 2014Applicant: BASF SEInventors: Jochen Dietz, Richard Riggs, Nadege Boudet, Jan Klaas Lohmann, Ian Robert Craig, Egon Haden, Erica May Wilson Lauterwasser, Bernd Mueller, Wassilios Grammenos, Thomas Grote
-
Patent number: 8765698Abstract: Products and methods are provided for the restoring the endogenous expression of theta-defensins, such as retrocyclin-1, in mamallian cells. The present invention also includes products and methods for inhibiting sexually transmitted virus entry, e.g., HIV-1 virus entry, into a mammalian cell via, for example, administering to a subject an amount of a read-through mediating agent sufficient to induce exogenous expression of an amount of retrocyclin nonapeptides in the mammalian cell.Type: GrantFiled: February 3, 2010Date of Patent: July 1, 2014Assignee: University of Central Florida Research Foundation, Inc.Inventor: Alexander M. Cole
-
Publication number: 20140179518Abstract: The present invention relates to pesticidal mixtures comprising as active components 1) at least one cyanosulfoximine compound I of the formula I wherein R1, R2 and G are defined as in the description; and 2) at least one fungicidal compounds II selected from azoles, strobilurins, carboxamides, carbamates, heterocyclic and various other compounds as defined in the description, in synergistically effective amounts. The invention relates further to methods and use of these mixtures for combating insects, arachnids or nematodes and harmful fungis in and on plants, and for protecting such plants being infested with pests, especially also for protecting seeds.Type: ApplicationFiled: December 20, 2013Publication date: June 26, 2014Applicant: BASF SEInventors: Delphine BREUNINGER, Henricus Maria Martinus BASTIAANS, Wolfgang VON DEYN, Matthias POHLMAN, Juergen LANGEWALD, Egon HADEN
-
Patent number: 8715623Abstract: A dispersible powder composition comprises aminoglycoside for delivery to the lungs. The composition is effective to provide a therapeutically effective therapy via administration of less than 6 respirable unit doses by inhalation, wherein each unit dose comprises a volume of 0.30 to 0.95 mL.Type: GrantFiled: October 31, 2007Date of Patent: May 6, 2014Assignee: Novartis AGInventors: Thomas E. Tarara, Jeffry G. Weers, Geraldine Venthoye
-
Publication number: 20140072620Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: ApplicationFiled: November 15, 2013Publication date: March 13, 2014Applicant: Insmed IncorporatedInventor: Jeff Weers
-
Publication number: 20140066365Abstract: A product comprising at least one given antibiotic and a calixarene for use as medicament.Type: ApplicationFiled: April 11, 2012Publication date: March 6, 2014Inventors: Marion Grare, Raphaël, Emmanuel Duval
-
Publication number: 20140037709Abstract: A system for the protection against degradation during pelleting of one or more physiologically or pharmacologically active substances, comprising compositions in the form of micro particles or granules, particularly for use in the zootechnical and/or veterinary field. The micro particles include a core which contains one or more substances having a pharmacological action, food supplements or diagnostic media, said one or more substances being characterized by the presence, within their chemical structure, of a basic functional group, specifically including an amine functional group. The core comprises also one or more carboxylic acids and/or their salts and eventually one or more excipients. Said core is coated by an outer layer of fats or waxes, and preferably by a mixture of glyceride of fatty acids.Type: ApplicationFiled: August 2, 2013Publication date: February 6, 2014Applicant: Kemin Industries, Inc.Inventors: Sarah E. Boucher, Jill Davidson, Bill L. Miller
-
Publication number: 20140038914Abstract: This invention relates to a compound of Formula 1A: or a pharmaceutically acceptable salt thereof; wherein R1 to R4, R7, R9 to R12 and Y are as defined herein. The invention further relates to pharmaceutical composition comprising said compound or a pharmaceutically acceptable salt thereof; and method of using same for reducing or reversing bacterial resistance to at least one aminoglycoside antibiotic.Type: ApplicationFiled: January 17, 2012Publication date: February 6, 2014Applicant: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITYInventors: Karine Auclair, Kenward Vong
-
Publication number: 20140018312Abstract: The present invention includes novel compounds based on the tomatidine skeleton as well as composition comprising these compounds alone and in combination with known compounds, which exhibit antimicrobial activity against extracellular or intracellular electron transport-deficient microbes and/or increase the antimicrobial activity of aminoglycoside antibiotics against their targets, and which are useful as antibacterial agents for treatment or prophylaxis of monomicrobiotic or polymicrobic bacterial infections or for the reduction of antibiotic resistance development in animals or in humans, or for use as antiseptics or agents for sterilization or disinfection.Type: ApplicationFiled: February 15, 2012Publication date: January 16, 2014Applicant: SOCPRA SCIENCES ET GENIE, S.E.C.Inventors: François Malouin, Gabriel Mitchell, Kamal Bouarab, Eric Marsault, Felix Chagnon, Simon Boulanger, Isabelle Guay
-
Publication number: 20130338059Abstract: This disclosure relates to methods for differentiating between mammals having active and latent Tuberculosis disease, by determining the percentage of polyfunctional CD4+ T-cells expressing TNF-alpha, IFN-gamma, and IL-2, or by determining expression of IL-17.Type: ApplicationFiled: December 22, 2011Publication date: December 19, 2013Applicant: Centre Hospitalier Universitaire VaudoisInventors: Giuseppe Pantaleo, Alexandre Harari, Matthieu Perreau
-
Publication number: 20130287866Abstract: Use of nitric oxide amino acid esters for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation, such as peripheral vascular disease. The nitric oxide amino acid esters may be co-administered with an antimicrobial in topical or transdermal compositions for improving vascular circulation, and prophylaxis or treatment of a condition associated with impaired blood circulation.Type: ApplicationFiled: October 26, 2011Publication date: October 31, 2013Applicant: ORAL DELIVERY TECHNOLOGY LTD.Inventor: Michael Farber
-
Patent number: 8529935Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: GrantFiled: January 29, 2010Date of Patent: September 10, 2013Assignees: Mero S.R.L., Novagenit S.R.L.Inventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20130224258Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.Type: ApplicationFiled: February 12, 2013Publication date: August 29, 2013Applicant: MICROBION CORPORATIONInventor: Microbion Corporation
-
Patent number: 8492334Abstract: Biodegradable polymeric microparticle compositions containing one or more active agents, especially those useful for treating or preventing one or more diseases or disorders of the eye, and methods of making and using thereof, are described. In a preferred embodiment, the microparticle compositions contain one or more active agents useful for managing elevated intraocular pressure (IOP) in the eye. Relatively hydrophilic, and preferably carboxylated, polymeric materials such as PLGA are used for a drug such as timolol maleate, which is relatively water soluble, to increase drug loading. Higher molecular weight polymers, as well as the ratio of LA (which has a longer degradation time, up to one to two years) to GA (which has a short degradation time, as short as a few days to a week), are used to provide release over a longer period of time.Type: GrantFiled: June 18, 2008Date of Patent: July 23, 2013Assignees: Yale University, University of Iowa Research FoundationInventors: Erin Lavik, Young H. Kwon, Markus Kuehn, Sandeep Saluja, James Bertram, John Huang
-
Publication number: 20130171210Abstract: Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.Type: ApplicationFiled: March 1, 2013Publication date: July 4, 2013Applicant: MICROBION CORPORATIONInventor: MICROBION CORPORATION
-
Publication number: 20130071469Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: Insmed IncorporatedInventor: Insmed Incorporated
-
Publication number: 20130052172Abstract: The present disclosure defines a method for identifying and/or treating risk and/or occurrence of cardiac defect. As is shown herein, microbiomes are reproducibly and detectably associated with cardiac defect risk factors and changes to the microbiome can directly alter cardiac defect risk. The present disclosure demonstrates that microbial signatures can be used to characterize components of microbiomes that associate with altered risk or occurrence of cardiac defects and to identify treatments to reduce risk or severity of cardiac defects.Type: ApplicationFiled: April 7, 2012Publication date: February 28, 2013Inventor: John Edward Baker
-
Publication number: 20130052260Abstract: A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed.Type: ApplicationFiled: October 30, 2012Publication date: February 28, 2013Applicant: Insmed IncorporatedInventor: Insmed Incorporated
-
Publication number: 20130045941Abstract: Embodiments of the invention relate generally to formulations comprising dimethylsulfoxide (DMSO) alone or in combination with methylsulfonylmethane (MSM), and one or more therapeutic agents, and uses of such formulations to treat infectious diseases. In several embodiments, such formulations are effective in treating drug-resistant infectious diseases, for example, drug-resistant tuberculosis.Type: ApplicationFiled: October 29, 2010Publication date: February 21, 2013Applicant: Abela Pharmaceuticals, Inc.Inventors: Colette Cozean, Rodney Benjamin, Anthony Keller, Jeff Varelman
-
Publication number: 20130022661Abstract: A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having structural properties so as to aid in the generation of new bone tissue and eventually be reabsorbed in the newly formed bone tissue. This structural and bio-remodable implant reduces, if not eliminates, the need to remove the implantable member from the patient once new bone tissue is formed. A kit including the implantable devices and bone growth material is disclosed. Methods of use are also disclosed.Type: ApplicationFiled: July 21, 2011Publication date: January 24, 2013Applicant: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20120329745Abstract: The present invention provides a composition having an excellent controlling activity on plant disease. The composition comprising the compound represented by the formula (1) and one or more antibiotic fungicidal compound selected from the group (A) shows an excellent controlling activity on a plant disease.Type: ApplicationFiled: March 2, 2011Publication date: December 27, 2012Applicant: SUMITOMO CHEMICAL COMPANY, LIMITEDInventors: So Kiguchi, Soichi Tanaka, Mayuko Ozawa, Atsushi Iwata
-
Patent number: 8336545Abstract: A method of treating a patient with a pulmonary disease, where the method includes delivering a dose of aerosolized medicament intermittently to a ventilator circuit coupled to the respiratory system of the patient. Also, a method of treating a patient with a pulmonary disease, where the method includes taking the patient off a ventilator, and administering to the patient, a nebulized aerosol comprising from about 100 ?g to about 500 mg of a medicament. Also a method of treating a patient with a pulmonary disease, the method comprising administering an aerosolized first medicament comprising amikacin to the patient and administering, systemically a second medicament comprising an antibiotic to the patient that also treats the pulmonary disease, wherein a resulting amikacin concentration in the lung and/or pulmonary system is therapeutically-effective, and an amount of the systemically administered antibiotics is reduced.Type: GrantFiled: January 16, 2007Date of Patent: December 25, 2012Assignee: Novartis Pharma AGInventors: James B. Fink, John Power, Ehud Ivri, Kevin J. Corkery
-
METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR TREATING INFECTIOUS DISEASES
Publication number: 20120264678Abstract: Disclosed are methods of treating infectious diseases comprising administering to an animal, a therapeutically effective amount of a heterocyclic compound. The animal is a mammal, preferably a human or a rodent.Type: ApplicationFiled: June 6, 2012Publication date: October 18, 2012Applicant: NEREUS PHARMACEUTICALS, INC.Inventor: Michael Palladino -
Publication number: 20120245107Abstract: The invention relates to formulations of an antimicrobial agent, a lipid, and optionally a surfactant, and uses thereof for reducing the proliferation and viability of microbial agents.Type: ApplicationFiled: June 7, 2012Publication date: September 27, 2012Inventors: William Henry, Henk-Andre Kroon, Linda Summerton
-
Publication number: 20120122769Abstract: Antibacterial antisense compounds and methods of their use in treating a Mycobacterium tuberculosis infection in a mammalian host are disclosed. The compounds include an antisense oligonucleotide conjugated to a carrier peptide that significantly enhances the antibacterial activity of the oligonucleotide. The antisense oligonucleotides contain 10-20 nucleotide bases and have a targeting nucleic acid sequence complementary to a target sequence containing or within 20 bases, in a downstream direction, of the translational start codon of a bacterial mRNA that encodes a bacterial protein essential for bacterial replication, where the compound binds to a target mRNA with a Tm of between 45° to 60° C. The carrier peptide is an arginine-rich peptide containing between 6 and 14 amino acids.Type: ApplicationFiled: November 10, 2011Publication date: May 17, 2012Applicant: AVI BIOPHARMA, INC.Inventor: Patrick L. Iversen
-
Publication number: 20120101055Abstract: A patient suffering from an endobronchial infection is treated by administering to the patient for inhalation a dose of less than about 4.0 ml of a nebulized aerosol formulation comprising from about 60 to about 200 mg/ml of an aminoglycoside antibiotic, such as tobramycin, in a physiologically acceptable carrier in a time period of less than about 10 minutes. Unit dose devices for storage and delivery of the aminoglycoside antibiotic formulations are also provided.Type: ApplicationFiled: November 14, 2011Publication date: April 26, 2012Inventors: Robert John Speirs, Barbara Ann Schaeffler, Peter Bruce Challoner
-
Publication number: 20120027723Abstract: The present invention relates to taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration. More particularly the invention relates to a substance selected from the group consisting of taurine, a taurine precursor, a taurine metabolite, a taurine derivative, a taurine analog and a substance required for the taurine biosynthesis for the prevention and treatment of a disease associated with retinal ganglion cell degeneration.Type: ApplicationFiled: July 26, 2011Publication date: February 2, 2012Inventor: Serge Picaud
-
Publication number: 20120021038Abstract: A wound spacer device comprising multiple beads connected by non-absorbable suture material is disclosed. The device can be applied, for example, by a first responder to an injured individual, or can be applied by a trauma treatment facility, such as a Level 2 medical unit. In typical embodiments the device allows for site-specific controlled elution of an antimicrobial agent, such as Tobramycin, including defined elution over a period of time, such as 48 or 72 hours.Type: ApplicationFiled: September 23, 2011Publication date: January 26, 2012Applicant: Surmodics, Inc.Inventors: Tim M. Kloke, Steven J. Keough, Nathan Lockwood, Margaret R. Gardner, Robert W. Hergenrother, Ralph A. Chappa
-
Publication number: 20110311593Abstract: The invention relates to N-hydroxylated amidines, guanidines and aminohydrazones for application on the skin. In particular, the invention relates to transdermal therapeutic systems containing N-hydroxylated amidines, guanidines and aminohydrazones as a prodrug, and to methods for producing and using such systems.Type: ApplicationFiled: February 5, 2010Publication date: December 22, 2011Inventors: Rudolf Matusch, Hans-Rainer Hoffmann, Bodo Asmussen, Andreas Koch
-
Patent number: 8071535Abstract: Reagents and methods useful for the synthesis of conjugates comprising guanidinylated cyclic acetals are provided. Also provided are methods for increasing the cellular uptake of various therapeutic compounds and treatment modalities using these conjugates.Type: GrantFiled: September 10, 2004Date of Patent: December 6, 2011Assignee: The Regents of the University of CaliforniaInventors: Yitzhak Tor, Nathan Luedtke
-
Publication number: 20110280921Abstract: The present invention relates to hydrogels endowed with antibacterial properties, to be used for injection in damaged bones or in the production of antibacterial coatings of prostheses for implant in the human or animal body, obtained by loading with antibacterial agents hydrogels formed by derivatives of hyaluronic acid; the invention also relates to a kit of parts for producing the antibacterial hydrogels.Type: ApplicationFiled: January 29, 2010Publication date: November 17, 2011Applicants: NOVAGENIT S.R.L., MERO S.R.LInventors: Gaetano Giammona, Giovanna Pitarresi, Fabio Palumbo, Carlo Luca Romano, Enzo Meani, Edgardo Cremascoli
-
Publication number: 20110218166Abstract: The present invention has as its objective to provide mucoadherent compositions with enhanced properties of bioadhesivity, consistency, stability and vaginal pH regulation. It can also be the carrier of an active principle for the treatment or prophylaxis of disturbances or diseases caused in mucosa, particularly in the vaginal tract, as well as their use.Type: ApplicationFiled: August 14, 2009Publication date: September 8, 2011Applicant: Incrementha PD&I - Pesquisa, Desenvolvimento e Inovecao de Famacos e Medicamentos Ltda.Inventors: Haline Fernanda Santana Castanho, Lupércio Calefe
-
Publication number: 20110189125Abstract: Compositions and methods for modulating HSP70 function, particularly for the targeted killing of cancer cells, are disclosed.Type: ApplicationFiled: March 18, 2011Publication date: August 4, 2011Applicants: Trustees of the University of Pennsylvania, Fox Chase Cancer CenterInventors: Donna L. George, Julia I-Ju Leu, Maureen Murphy